Navigation Links
Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
Date:4/6/2009

Company extends the term and expands territorial rights of its exclusive licensee in Japan after Itochu reaches market penetration milestone of 100 customer manufacturers in Japan for cosmeceutical and dietary supplement products using patented AC-11(R) (formerly known as C-Med- 100(R))

Increase in consumer demand fueled by results of new research showing that that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin.

NEW YORK, April 6 /PRNewswire-FirstCall/ -- Optigenex Inc. (Pink Sheets: OPGX) announced today the signing of an extended and expanded new contract with its distribution partner in Asia (Itochu Corporation). Under the new license, Itochu has the right to market AC-11(R) technology exclusively in Japan and non-exclusively throughout the rest of Asia (Additional details were not disclosed). The new agreement represents the fulfillment of an important strategic objective to the company in terms of its business development plans for the Asia and further validates its business model in Japan and other countries in the region.

To date, Itochu has introduced AC-11(R) to over 100 companies in the cosmetic and dietary supplement market, with over 130 products containing AC-11(R) being marketed and sold. AC-11(R) is a patented, all-natural rain forest botanical extract that helps the body's natural ability to repair damage to its own DNA due to multiple causes, including harmful effects of UV radiation from over exposure to the sun, stress, environmental pollution and other toxins. In its standard bulk powder form, AC-11(R) supplement may be consumed orally or combined with liposomes and other delivery mechanisms for topical application on the skin.

The increase in demand for AC-11(R)-based products follows the issuance of a report in October 2008 by a leading French dermatological research center showing that orally administered AC-11(R) supplement increases the production of collagen III in the epidermis layer of the skin by stimulating expression of the COL3A1 gene. Collagen III is important for the development of skin and the cardiovascular system and for maintaining normal physiological functions in adult life. Results of the study suggest that oral and topical AC-11(R) products, when combined, are an inner and outer beauty solution to help reverse the signs of premature aging.

The French research, which was sponsored by Itochu, compliments earlier published third party studies demonstrating the effectiveness of AC-11(R) as a unique DNA repair adjuvant, as well as a natural inhibitor of pro-inflammatory agents and a natural immune system supporter.

Itochu partners with Optigenex under an Exclusive Supply and Trademark Licensing Agreement to market AC-11(R) bulk material and consumer products containing AC-11(R) under sublicenses in Japan and several other Asian countries.

Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited by our new agreement with Itochu and equally with the results of the French laboratory study and by Itochu's joint commitment with us to expand the science behind AC-11(R). The personal care products market in Japan and the rest of Asia continues to grow. With Itochu's efforts, we are confident that Optigenex and AC-11(R) will be part of that growth."

Yusuke Itou of Itochu Corporation added the following, "We are very pleased with the positive reception AC-11(R) has received from manufacturers in Japan and our expanding role in marketing AC-11(R) in Southeast Asia. We anticipate strong demand for additional AC-11(R)-based products in the remainder of 2009 and beyond as consumer awareness of the benefits of AC-11(R) for healthy DNA maintenance and natural skin collagen production increases."

About ITOCHU Corporation:

Itochu Corporation is one of Japan's leading trading companies and is engaged in a wide variety of businesses, including food products, personal care products, textiles, technology multimedia, metals, energy, chemicals, forest products, retail and financial services. Itochu has approximately 45,690 employees maintains over 130 offices and owns over 651 subsidiaries and affiliates around the world. Itochu's sales last year reached 11.58 trillion yen (U.S. $95 billion.) (Update sales revenue and company figures)

About Optigenex Inc.:

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11(R) (Formerly known as C-MED-100(R)) a patented compound as it core product. AC- 11(R) is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa. For more information about Optigenex please email the company at: dzwiren@optigenex.com


'/>"/>
SOURCE Optigenex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
4. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
7. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
8. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):